Autor:	Nizar Tannir, Arlene Siefker-Radtke, Robert Figlin
Rok vydání:	2022
Zdroj:	Kidney Cancer Journal. 20:15-20
ISSN:	1933-0871 1933-0863
DOI:	10.52733/kcj20n1-rt
Popis:	In this roundtable discussion, renowned cancer experts analyze the potential immunomodulatory capabilities of bempegaldesleukin (BEMPEG; NKTR- 214) in combination with an immune checkpoint inhibitor (CPI; anti-PD-1) in the therapeutic landscape of advanced renal cell carcinoma (aRCC) and other genitourinary cancers. The expert panel also shared their perspectives regarding the latest data from ongoing clinical trials which continue to show an encouraging efficacy and safety, risk/benefit of BEMPEG plus CPI combination.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d662b10a1132851b1913c6d3a3ea9335 https://doi.org/10.52733/kcj20n1-rt Zobrazit plný text záznamu